FAIRBANKS, Alaska, June 25, 2025 /PRNewswire/ - Contango ORE, Inc. ("Contango" or the "Company") (NYSE American: CTGO) is pleased to announce that the Peak Gold...
The ITC compared all published Phase 3 data of these treatments, leveraging longitudinal results, and findings reinforce the importance of consistent, sustained disease control in managing a chronic autoantibody disease like gMG
SAN DIEGO, June 24, 2025 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP announces that it is investigating potential claims on behalf of investors of Hims & Hers Health, Inc. (NYSE: HIMS) regarding possible violations of federal securities laws. Investors who purchased Hims & Hers securities may be eligible to recover losses stemming from alleged misrepresentations and omissions made by the company and its executives.
The BAFF- and APRIL-targeted therapies market is experiencing steady growth driven by the rising prevalence of autoimmune diseases such as systemic lupus erythematosus (SLE),...
The BAFF- and APRIL-targeted therapies market is experiencing steady growth driven by the rising prevalence of autoimmune diseases such as systemic lupus erythematosus (SLE),...
The health and wellness market size is expected to be worth over USD 11 trillion by 2034, increasing from USD 6.57 trillion in 2024, with a CAGR of 5.50%. The market of health and wellness is driven by rising health awareness, an aging population, technological advancements, growing health consciousness, and supportive government initiatives.
The health and wellness market size is expected to be worth over USD 11 trillion by 2034, increasing from USD 6.57 trillion in 2024, with a CAGR of 5.50%. The market of health and wellness is driven by rising health awareness, an aging population, technological advancements, growing health consciousness, and supportive government initiatives.
En cas d’autorisation, le daratumumab deviendra la première option thérapeutique autorisée pour les patients atteints d’un myélome multiple indolent et présentant un risque élevé de développer un myélome multiple, offrant le potentiel de blocage de la progression de la maladie1
Unites Pharma Marketing, PR & Communications, New Product Planning & Commercialization, and Medical Affairs Communities; Thought Leaders from AbbVie, AstraZeneca, BMS, GSK, Johnson & Johnson, NBCUniversal, Pfizer, Takeda and More Deliver Unparalleled Education
The ITC compared all published Phase 3 data of these treatments, leveraging longitudinal results, and findings reinforce the importance of consistent, sustained disease control in managing a chronic autoantibody disease like gMG